/Biogen%20logo%20is%20seen%20at%20its%20headquarters%20in%20Cambridge%2C%20Massachusetts%20By%20Tada%20Images.jpeg)
With a market cap of $29.6 billion, Biogen Inc. (BIIB) is a leading biotechnology company dedicated to pioneering innovative science to develop transformative medicines that improve patients' lives. By leveraging a deep understanding of human biology and advanced therapeutic approaches, the company strives to deliver first-in-class treatments while creating long-term value for shareholders and communities.
The Cambridge, Massachusetts-based company is set to unveil its fiscal Q2 2026 results before the market opens on Wednesday, Jul. 29. Ahead of this event, analysts expect BIIB to report an adjusted EPS of $3.24, down 40.8% from $5.47 in the year-ago quarter. However, it has surpassed Wall Street's bottom-line estimates in each of the past four quarters.
